Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms.

Autor:	King-Kallimanis BL; LUNGevity Foundation, Chicago, Illinois., Ferris A; LUNGevity Foundation, Chicago, Illinois., Dropkin L; Edge Research, Arlington, Virginia., Molina M; Edge Research, Arlington, Virginia., Redway L; Edge Research, Arlington, Virginia., Gerber DE; Harold C. Simmons Comprehensive Cancer Center, University of Texas (UT) Southwestern Medical Center, Dallas, Texas., Grant TL; LUNGevity Foundation, Chicago, Illinois., Roy UB; LUNGevity Foundation, Chicago, Illinois.
Jazyk:	angličtina
Zdroj:	JTO clinical and research reports [JTO Clin Res Rep] 2023 Sep 14; Vol. 4 (10), pp. 100575. Date of Electronic Publication: 2023 Sep 14 (Print Publication: 2023).
DOI:	10.1016/j.jtocrr.2023.100575
Abstrakt:	Introduction: The purpose of the informed consent form (ICF) is to outline the risks and benefits of an interventional clinical trial to potential participants. The aim of this study was to explore the feasibility of a short addendum to the ICF, summarizing key points most relevant to potential participants. Methods: A sample of 20 ICFs was reviewed against the requirements of the U.S. federal regulation documents and assessed for readability. Alongside the ICF review, we conducted focus groups and one-on-one interviews with people with lung cancer (n = 9) to learn what information was most important when considering participation in a clinical trial using a hypothetical phase 3 ICF. Results: The 20 ICFs reviewed were from phases 1 to 3, expanded-access, and single-patient trials covering predominantly NSCLC; 60% were global. The mean length of the ICFs was 21 (range: 15-34) pages. The average reading level was tenth grade whereas the average U.S. reading level was eighth grade. Readability varied by section, the "purpose of the study" section had the highest reading level. In the qualitative research component, participants were "overwhelmed" by the hypothetical ICF. Participants were also asked to list information for the addendum; their suggestions broadly map to federal regulations. An addendum with reference to sections in the ICF for additional details was well received. Conclusions: The variations in ICF architecture and readability make it difficult for patients to make an informed decision to participate in a clinical trial. Implications extend beyond lung cancer, highlighting key areas for ICF improvements and providing a roadmap for developing a patient-centric addendum. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu